CJC-1295 contraindications: who should not use it

Last updated 2026-07-26

What is CJC-1295 and why do contraindications matter here

CJC-1295 is a synthetic analogue of growth hormone releasing hormone (GHRH). It binds the GHRH receptor on pituitary somatotrophs and pushes them to release more growth hormone, which in turn raises IGF-1. It comes in two forms that get confused constantly: CJC-1295 without DAC (also sold as "Mod GRF 1-29") has a short half-life of roughly 30 minutes, while CJC-1295 with DAC binds serum albumin and stretches its half-life out to about 6 to 8 days ^[1]. That difference changes dosing frequency and, arguably, the risk profile, since DAC versions keep GH/IGF-1 elevated for much longer between doses. Here is the uncomfortable truth up front: there is no FDA-approved prescribing label for CJC-1295, so there is no official "contraindications" section written by a regulatory body for this exact molecule. The FDA has not approved CJC-1295 for any human indication, and in 2023 it placed several GHRH-related peptides, including growth hormone releasing peptides, on its list of bulk drug substances that compounding pharmacies may not use, citing safety concerns ^[2]. Everything below is derived from GH-axis physiology, related drug labels (like GHRH analogues that are FDA-approved, such as tesamorelin), and the FDA's own public safety communications, not from a manufacturer's package insert for CJC-1295 itself. That distinction matters more here than in almost any other supplement or peptide category. For background on the compound's mechanism and study base, see our CJC-1295 overview.

Who should not use CJC-1295 (absolute contraindications)

Based on how GH and IGF-1 behave in the body, a short list of conditions is widely treated as an absolute stop sign by clinicians who work with GH-axis drugs, even though CJC-1295 itself lacks a formal label. Active or suspected malignancy is the clearest one. IGF-1 is a growth factor. It supports cell proliferation, and there is long-standing concern in endocrinology that driving IGF-1 up in someone with an active tumor could accelerate its growth. This is why tesamorelin, an FDA-approved GHRH analogue used for HIV-associated lipodystrophy, carries a label warning against use in patients with "disruption of the hypothalamic-pituitary axis due to hypophysectomy, hypopituitarism, pituitary tumor/surgery, or head irradiation" and states it "is not indicated" for other weight-loss uses, alongside contraindication in patients with active malignancy ^[3]. If tesamorelin's own approved label draws that line, there is no rational argument for treating an unapproved GHRH analogue like CJC-1295 more casually in someone with cancer. Pregnancy and breastfeeding are also firm no's. There is no human safety data on CJC-1295 in pregnancy, and GH and IGF-1 both cross into fetal and neonatal physiology in ways that have not been studied for this compound at all. Absence of data is not reassurance here; it is the reason to avoid it. Acute critical illness is a specific, evidence-backed contraindication for GH-axis stimulation generally. A widely cited randomized trial in critically ill ICU patients found that high-dose recombinant human growth hormone increased mortality compared to placebo, with in-hospital mortality of 39% in the GH-treated groups versus 20% in the placebo group ^[4]. That trial used GH itself, not a GHRH secretagogue, but it is the reason intensivists are wary of pushing the GH axis in anyone acutely, critically ill, and it is a reasonable line to extend to CJC-1295. Known hypersensitivity to CJC-1295 or its excipients is a straightforward contraindication for any injectable, though it is one people will not know about until first exposure. Covering related side effects in more depth: cjc 1295 side effects.

Does diabetes or blood sugar control affect CJC-1295 use

Yes, and this is one of the more predictable interactions in the GH-axis world. Growth hormone antagonizes insulin action, meaning it tends to raise blood glucose and can worsen insulin resistance. This isn't folklore; it is basic endocrine physiology and it is documented in the labels of GH-axis drugs. The tesamorelin label states the drug "may increase the risk of new-onset diabetes mellitus" and instructs monitoring of blood glucose, noting that in clinical trials, glucose levels increased in some patients ^[3]. Genotropin (recombinant human GH) prescribing information similarly warns that GH "may reduce insulin sensitivity" and lists glucose intolerance and diabetes as risks requiring monitoring ^[5]. For someone with type 1 or poorly controlled type 2 diabetes, adding a GHRH analogue on top of an already unstable glucose picture is a real risk, not a theoretical one. If you have diabetes and are still considering this, insulin doses and glucose monitoring would need active medical supervision, and self-directed use without a clinician watching your labs is a bad idea.

Can people with pituitary or hormone conditions use CJC-1295

No, not without specialist involvement, and often not at all. CJC-1295 works by stimulating the pituitary gland directly. If the pituitary itself is damaged, removed, or dysfunctional (from surgery, tumor, radiation, or a condition like hypopituitarism), the drug has nothing to act on, and the physiologic feedback loops that normally keep GH in a safe range are already broken. The tesamorelin label explicitly excludes patients with pituitary axis disruption from hypophysectomy, hypopituitarism, pituitary tumor or surgery, or head irradiation ^[3], and that logic transfers directly to any GHRH analogue including CJC-1295. People already on prescribed GH replacement therapy, thyroid hormone replacement, or being treated for acromegaly are managing a hormone axis that a second, unsupervised GH secretagogue could destabilize in either direction. This is a "talk to your endocrinologist first" situation, full stop, not a "stack it and see" situation.

Is CJC-1295 safe with heart disease or fluid retention issues

This is a gray zone worth taking seriously rather than dismissing. GH and IGF-1 elevation are associated with fluid retention, and in people with existing heart failure or edema-prone conditions, that fluid shift is not trivial. The Genotropin label lists edema as an adverse reaction and warns about use in patients with pre-existing fluid retention conditions ^[5]. Reports of peripheral edema, joint pain, and carpal-tunnel-like symptoms are common enough in GH-axis therapy that they show up across multiple related drug labels, more than isolated case reports. Someone with congestive heart failure, significant edema, or uncontrolled hypertension should treat CJC-1295 as high-risk until a cardiologist has weighed in, not because there is a CJC-1295-specific heart study proving harm, but because the physiologic mechanism (sodium and water retention via the GH axis) is well established in adjacent, approved drugs.

CJC-1295 with DAC vs without DAC: does the contraindication picture change

The DAC distinction is mostly about duration and magnitude of exposure, not a different mechanism, but that duration matters for risk. CJC-1295 without DAC clears from the body in roughly 30 minutes, producing a GH pulse that resembles the body's own natural GH release pattern ^[1]. CJC-1295 with DAC binds albumin and persists for about 6 to 8 days, producing sustained elevation of GH and IGF-1 rather than a pulse ^[1]. In practical terms, that means anyone with a contraindication above (active malignancy, uncontrolled diabetes, cardiac fluid issues) faces a longer window of exposure and less ability to "stop and clear" quickly with the DAC version if something goes wrong. | Feature | CJC-1295 (no DAC) | CJC-1295 with DAC |

Why is CJC-1295 usually paired with ipamorelin, and does that change the risk profile

CJC-1295 and ipamorelin are commonly stacked because they act on two different receptors that both increase GH release: CJC-1295 stimulates the GHRH receptor, while ipamorelin is a ghrelin-receptor agonist (a growth hormone secretagogue, similar mechanistically to the approved drug macimorelin, which is used diagnostically for adult GH deficiency testing) ^[6]. In theory, combining a GHRH-receptor agonist with a ghrelin-receptor agonist produces a larger, more synchronized GH pulse than either alone, because the two receptors work through different intracellular signaling pathways. That rationale is physiologically plausible, but it is not the same as saying the combination has been studied in controlled human trials for safety or efficacy as a stack. It has not, at least not in published clinical research at the doses and frequencies commonly discussed outside clinical settings. Ipamorelin itself is generally described in the literature as having a cleaner side-effect profile than older ghrelin-receptor agonists (less effect on cortisol and prolactin), but "cleaner than X" is not the same as "safe for everyone." The contraindications for the combination are the union of the contraindications for each drug, not a smaller set. If anything, stacking two GH-axis stimulators means less margin for error if you have an underlying condition, because you are pushing the same pathway (GH/IGF-1 elevation) from two directions at once.

What are the warning signs that mean stop and see a doctor

A few symptoms are red flags rather than "normal adjustment," and knowing them matters more than any theoretical contraindication list. Severe or worsening headache with visual changes can signal intracranial pressure changes; GH-axis drugs have been associated with idiopathic intracranial hypertension in labels for related products ^[5]. Numbness or tingling in the hands, especially at night, can indicate carpal-tunnel-like fluid compression, a documented GH-axis adverse effect ^[5]. Rapid, unexplained swelling in the ankles, face, or hands points to fluid retention. New or worsening high blood sugar symptoms (excess thirst, frequent urination, fatigue) should prompt a glucose check given the well-documented insulin-antagonist effect of GH ^[3][5]. Any injection-site reaction that spreads, or systemic allergic symptoms (hives, throat tightness, difficulty breathing) after a dose, is an emergency, not a "wait and see." None of these symptoms are unique to CJC-1295, but they are the same symptoms clinicians watch for with FDA-approved GH-axis drugs, and there is no reason to think an unapproved analogue is exempt from the underlying physiology.

Is CJC-1295 legal to buy and use, and does that affect safety oversight

This is where contraindications intersect with regulatory reality, and it is worth being blunt about it. CJC-1295 is not FDA-approved as a drug for any indication in the United States. In 2023, the FDA finalized a rule placing five GHRH-related bulk substances, including sermorelin-related and growth-hormone-releasing peptides, on the category 2 list of substances that cannot be used in compounding under section 503A or 503B of the Federal Food, Drug, and Cosmetic Act, specifically citing safety concerns about "significant adverse events" associated with unapproved GH secretagogues ^[2]. That regulatory status means there is no FDA-reviewed label, no REMS program, no pharmacovigilance database tracking adverse events specific to CJC-1295 the way there would be for an approved drug. It also means product quality varies enormously depending on where it is sourced; purity, dosing accuracy, and sterility are not guaranteed by any government inspection process the way they would be for a prescription drug manufactured under FDA-regulated conditions. What this means practically: whatever contraindications apply based on physiology (above) are being self-managed by the user or, in some cases, an off-label prescribing clinician, without the safety net that normally exists for pharmaceutical drugs. If you are going to use it despite that gap, working with a provider who reviews your health history and sources from a legitimate pharmacy is meaningfully safer than an anonymous online seller. See cjc 1295 for sale for how sourcing quality affects this.

How does CJC-1295 interact with other medications

There is no published human drug-interaction study specific to CJC-1295, so this section is inference from the mechanism, not direct trial data, and should be read that way. Corticosteroids (like prednisone) can blunt GH's effects and complicate glucose control further, since both corticosteroids and GH push blood sugar upward independently. Insulin and oral diabetes medications may need dose adjustment if GH secretion increases meaningfully, since GH raises insulin resistance ^[3][5]. Thyroid hormone replacement has a known interactive relationship with GH axis activity; GH can affect peripheral conversion of thyroid hormone, and the Genotropin label specifically notes that previously undiagnosed central hypothyroidism may become unmasked during GH treatment ^[5]. Sex hormone therapy (estrogen in particular) can affect IGF-1 generation in response to GH stimulation, an effect documented in oral estrogen users on GH replacement. Anyone on any of these medication classes should treat CJC-1295 as something to discuss with the prescribing clinician for that medication, not something to layer on independently.

Are there age-related contraindications (adolescents, older adults)

For adolescents and children, CJC-1295 has no pediatric safety data at all, and stimulating the GH axis in someone whose growth plates are still open carries real theoretical risk given how central GH is to skeletal growth regulation; this is squarely a "do not use" population absent a pediatric endocrinologist directing actual approved therapy for a diagnosed condition. For older adults, the concern shifts toward the malignancy and cardiovascular contraindications discussed above, since cancer incidence and cardiovascular disease prevalence both rise with age, and undiagnosed subclinical conditions become more likely. Age-related decline in GH/IGF-1 is normal physiology, sometimes called "somatopause," and reversing it artificially in an otherwise healthy older adult has not been shown in rigorous trials to produce net benefit; the 1990 Rudman study often cited by bodybuilding sources used recombinant GH, not CJC-1295, in a small trial of 21 men, and later, larger reviews have not confirmed a favorable risk-benefit ratio for GH-axis therapy in healthy aging.

What does provider-reviewed use actually look like

Provider-reviewed use means a clinician reviews your health history, current medications, and relevant labs (glucose, IGF-1 baseline, and a cancer risk screen appropriate to your age) before anything is dispensed, rather than a form that auto-approves after a credit card transaction. CJC-1295 Co works with a provider-reviewed process that connects people to that kind of clinical review rather than an anonymous checkout, and fulfillment runs through a licensed pharmacy partner rather than an unregulated seller. That does not turn CJC-1295 into an FDA-approved drug, and it does not erase the contraindications above. It does mean someone with actual medical training is looking at your specific situation before you inject anything, which is the single biggest safety lever available given how thin the formal contraindication data is for this molecule. For dosing specifics once a provider has cleared use, see cjc 1295 dosage and the cjc-1295 dac dosage calculator.

Frequently asked questions

Can I use CJC-1295 if I have a family history of cancer but no active diagnosis?

There is no CJC-1295-specific data on this. Because IGF-1 is a growth factor and the related drug tesamorelin is contraindicated in active malignancy ^[3], a strong family history is a reasonable topic to raise with a physician before use, including discussion of age-appropriate cancer screening, rather than an automatic disqualifier on its own.

Is CJC-1295 safe during breastfeeding?

No. There is no published safety data on CJC-1295 during lactation, and GH/IGF-1 physiology in nursing infants has not been studied for this compound. The absence of data is itself the reason to avoid it, not a gap to fill with personal risk tolerance.

Does CJC-1295 raise blood sugar even in non-diabetics?

It can. GH physiologically antagonizes insulin action, and related GHRH-axis drugs like tesamorelin carry FDA label warnings about new-onset diabetes and glucose elevation during treatment ^[3]. Non-diabetics with prediabetes or metabolic syndrome risk factors should have glucose monitored if using it.

What is the difference between CJC-1295 and CJC-1295 with DAC for safety purposes?

CJC-1295 without DAC clears in about 30 minutes; the DAC version persists 6 to 8 days by binding albumin ^[1]. The DAC version produces sustained rather than pulsatile GH/IGF-1 elevation, meaning any adverse reaction takes longer to resolve after the last dose.

Can CJC-1295 be used with insulin or diabetes medication?

Only under direct medical supervision. Because GH increases insulin resistance ^[3][5], adding CJC-1295 can require insulin or oral medication dose adjustments. Self-directed combination without a clinician monitoring glucose is a genuine safety risk, not a minor inconvenience.

Is CJC-1295 FDA-approved?

No. CJC-1295 is not FDA-approved for any indication, and the FDA placed related GHRH bulk substances on its restricted compounding list in 2023 due to safety concerns ^[2]. Any product sold as CJC-1295 is unapproved and unregulated by that specific label review process.

Why is CJC-1295 stacked with ipamorelin?

They act on different receptors (GHRH receptor and ghrelin receptor respectively) that both increase GH release, and the theory is a larger combined pulse ^[6]. That mechanistic rationale is plausible but has not been confirmed as safer or more effective by controlled human trials of the specific combination.

Can someone with a pituitary tumor history use CJC-1295?

This is a contraindication by extension. Tesamorelin, an approved GHRH analogue, is contraindicated in patients with pituitary tumor, pituitary surgery, hypophysectomy, or head irradiation history ^[3], and the same logic applies directly to CJC-1295 since both act on the same receptor and gland.

Does CJC-1295 cause swelling or fluid retention?

It can. GH-axis stimulation is linked to peripheral edema and fluid retention in related approved drug labels ^[5]. People with existing heart failure, significant edema, or poorly controlled hypertension should treat this as a real risk requiring a cardiologist's input before use.

Is CJC-1295 safe for older adults trying to reverse age-related GH decline?

There is no rigorous trial showing net benefit outweighs risk for healthy aging adults using GHRH analogues, and cancer/cardiovascular risk both rise with age, overlapping directly with the drug's clearest contraindication categories. This use case has more forum enthusiasm than clinical evidence behind it.

What symptoms mean I should stop CJC-1295 immediately?

Severe headache with vision changes, rapid swelling, hand numbness or tingling, signs of high blood sugar, or any allergic reaction (hives, throat tightness, breathing trouble) warrant stopping and seeking medical care immediately, since these overlap with documented GH-axis drug adverse effects ^[3][5].

Can children or adolescents use CJC-1295?

No, outside of a diagnosed condition managed by a pediatric endocrinologist using an actual approved therapy. There is no pediatric safety data for CJC-1295, and stimulating the GH axis in someone with open growth plates carries theoretical risks that have not been studied.

Sources

1. Journal of Clinical Endocrinology & Metabolism (Teichman et al., 2006) via NCBI PubMed abstract: CJC-1295 with DAC has an extended half-life supporting sustained GH/IGF-1 elevation over roughly 6-8 days versus a short-acting pulse for GHRH analogues without DAC
2. FDA, Federal Register final rule on bulk drug substances for compounding (2023): FDA placed GHRH-related bulk substances on the category 2 restricted list for compounding, citing safety concerns
3. FDA, Egrifta (tesamorelin) prescribing information: Tesamorelin label contraindicates use in patients with disrupted hypothalamic-pituitary axis and active malignancy, and warns of new-onset diabetes risk
4. New England Journal of Medicine, Takala et al. 1999: High-dose growth hormone increased mortality in critically ill ICU patients compared to placebo (39% vs 20% in-hospital mortality)
5. FDA, Genotropin (somatropin) prescribing information: Growth hormone therapy is associated with reduced insulin sensitivity, edema, and unmasking of central hypothyroidism
6. FDA, Macimorelin (Macrilen) prescribing information, NDA 209969: Macimorelin is an FDA-approved ghrelin receptor agonist used for adult GH deficiency diagnostic testing, illustrating the ghrelin-receptor mechanism shared with ipamorelin